Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 9/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 6/20 | 0.56 |
| ▸ | CD99 | P14209 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10026402 | 1.00 | PDE2A (0.67) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL12139442 | 1.00 | PDE2A (0.67) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL12139441 | 1.00 | PDE2A (0.67) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL24078849 | 0.90 | PDE2A (0.78) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10026379 | 0.90 | ADORA3 (0.61) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10026396 | 0.90 | ADORA3 (0.61) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10026359 | 0.89 | LMNA (0.57) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10026370 | 0.89 | LMNA (0.57) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL19366657 | 0.89 | LMNA (0.57) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10026368 | 0.89 | LMNA (0.57) | PDE2AADORA3ADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648188-B2 | Preparation of 2-chloro-9-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN, LTD. (TW) | 2014-02-11 | — | — | US | disclosed |
| US-20120010397-A1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-Beta-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN LTD. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010397-A1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-Beta-D-arabinofuranosyl)-adenine | HPRT1, TYMP, MTAP | PDE2A 642/4885ADORA3 71/4885ADORA2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.